Ariane Deep Knowledge AI Pharma Index
Ariane AI Pharma Index is an Actively Managed Certificate
An Actively Managed Certificate (“AMC”) is a structured product whose underlying asset is a portfolio of publicly listed companies, which is managed on a discretionary basis in this case by the Deep Knowledge Group during a specified term in accordance with a specific investment strategy.
Advantages of the AMCs
Investment strategies’ flexibility
Minimum public subscription amount of EUR 1,000
Have passporting rights in Europe
Low regulatory and legal costs
Index Overview
Ariane Deep Knowledge AI Pharma Index is designed to reflect the dynamics of the AI in Pharma sector. The performance of this industry has suggested a need for financial products that allow investors to benefit from the growth of the sector. These financial instruments will likewise assist the sector in continuing its growth.
​
Although past performance is not indicative of future performance, the expected Compound Annual Growth Rate for this sector is projected to be around 40% over the next 3 years.
CAGR
over the next 3 years
40
%
Our portfolio consists of 18 companies of different market and investment maturity levels, therefore its actual performance may differ from this expected CAGR.
Investment Strategy
AI in Pharma Industry Equities Basket
The AI in Pharma Equities Basket was created using a combination of cutting-edge technical and fundamental analyses. All of the companies in our portfolio can be described as AI in Pharma-focused or implementing AI solutions in the Pharmaceutical Industry.
Ariane AI Pharma Index Structure
Stabilizers
Big, well-known companies with great market performance. This set is considered to be the most reliable and suitable for risk-averse investors
Promising Companies
Promising companies tend to generate the highest returns, these companies also tend to have high volatility and low market caps
Performers
Companies of considerable size with good financial performance, pipelines and market strategies. These companies have big market share-growth potential.
Performance
The graph to the left depicts the cumulative returns generated by our investment strategy. This particular equities basked generated 35.5% return in the period between July 17, 2020 and July 16, 2021. The average daily return of this portfolio is 0.14%. This is almost twice as high as the returns generated by the IBB (iShares Biotechnology ETF) or the S&P 500, which generated 0.07% and 0.10% daily returns, respectively.
performance over 2020-2021
35
%
Try out our portfolio computing tool to learn more –
Ariane Deep Knowledge AI Pharma Index Features
Reflects development dynamics of the AI in Pharma Market​
Allows for objective assessment of underlying assets
​
Developed by seasoned experts in the AI in Pharma sector
​
Supported by cutting-edge analytical tools
​
Management Team
DMITRY KAMINSKIY
GENERAL PARTNER
Dmitry Kaminskiy is based in London. He is an experienced AI in Pharma industry investor and entrepreneur and the founder of Deep Knowledge Ventures and Aging Analytics Agency since 2014.
STEFAN HASCOET
HEAD OF SWISS OPERATIONS
Stefan Hascoet is based in Geneva. He is a Capital Markets Professional with 15 years of experience in investment products, derivatives and non-recourse lending facilities.
KATE BATZ
HEAD OF US OPERATIONS
Kate Batz is based in San Francisco. She is licensed to practice law in California and New York and has 20 years of experience as a Corporate Attorney.
ALEXANDER HOLODNY
HEAD OF UK OPERATIONS
Alexander Holodny is based in London. He is an experienced corporate finance and private equity professional.
IHOR KENDIUKHOV
DEPUTY MANAGING PARTNER
Ihor Kendiukhov is based in Berlin. He is a finance quant, AI and deep tech professional and leads the Big Data and Algorithmic Analytics Departments at Deep Knowledge Group.